The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are ...

The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...

Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list. Shares of Hims & Hers, which had capitalized ...

"GMA" shares an exclusive look inside the lab of the maker of such drugs as Mounjaro and Zepbound to show what it's doing to ...

The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...

Pharmaceutical giant Eli Lilly (LLY) is putting $4.5 billion toward building a new site to develop and manufacture drugs.

GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list. ...